 |
 |
|
|
|
| Dolutegravir |
 |
| 1051375-16-6 |
 |
| Dolutegravir is an experimental new drug under investigation for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Also known as S/GSK1349572 or just "572", the drug is under development by GlaxoSmithKline (GSK). Studies have shown dolutegravir to be effective in patients with resistance to the only currently available integrase inhibitor, raltegravir. |
 |
| Dolutegravir |
|
|
|
|
|
